精神分裂症谱系障碍患者抗NMDAR抗体血清阳性者的临床症状与心理社会功能:与血清阴性患者的病例对照比较
该病例对照比较汇总四个独立队列1114例精神分裂症患者,血清抗NMDAR抗体阳性率为3.7%(各队列范围3.1-4.0%)。阳性患者阴性症状分、一般症状分及PANSS总分均低于阴性患者,个人社会表现(PSP)评分优于阴性患者;作者认为抗体可能与不同形式的精神病性障碍相关,但结果待其他地区队列重复。
要点
- 精神分裂症患者血清抗NMDAR抗体阳性率为3.7%,各队列范围3.1-4.0%。
- 抗体阳性者阴性症状PANSS分15.8 vs 阴性者18.2(d=0.36,p=0.026)。
- 抗体阳性者PSP评分62.0 vs 阴性者53.5(d=0.52,p=0.014),功能相对较好。
核心结论
- 血清NMDAR抗体见于3-4%的精神分裂症患者,与相对较低的阴性症状严重度和相对较好的心理社会功能相关。
- 作者认为,尽管研究结果有待在其他地理区域的队列中重复,血清抗NMDAR抗体可能与不同形式的精神病性障碍相关。
- 这些发现可为未来预后和干预研究提供信息,以检验抗NMDAR抗体是否与特定病程或治疗反应相关。
研究设计与样本
- 本病例对照比较通过合并新的和已有的研究,纳入来自四个独立队列、经活细胞法检测(或可由研究者检测)抗NMDAR血清状态的精神分裂症患者。
- 纳入队列来自EULAST研究(在15个欧洲国家和以色列开展的试验)、OPTiMiSE研究(欧洲的干预性研究)以及PPiP1和PPiP2研究(在英国开展)。
- 仅分析具有完整阳性与阴性症状量表(PANSS)数据的患者;无参与者被诊断为自身免疫性脑炎或接受过该病治疗。
- 共收集四个队列1114例精神分裂症患者的个体数据,平均年龄28.6岁(SD 7.6),女性382例(34.3%)、男性732例(65.7%)。
- 所有分析均为探索性,未对多重检验进行调整;有生活经验者未参与本研究实施。
主要发现
- 41例(3.7%)参与者血清抗NMDAR抗体检测阳性,各队列范围3.1-4.0%。
- 抗NMDAR血清阳性患者阴性症状PANSS子量表平均分15.8(SD 6.4),低于血清阴性患者的18.2(SD 6.8)(Cohen's d=0.36,p=0.026)。
- 抗NMDAR血清阳性患者一般症状PANSS子量表平均分32.9(SD 8.9),低于血清阴性患者的36.1(SD 10.1)(d=0.33,p=0.029)。
- 抗NMDAR血清阳性患者PANSS总分平均65.5(SD 18.5),低于血清阴性患者的72.6(SD 19.3)(d=0.37,p=0.013)。
- 抗NMDAR阳性患者平均PSP评分62.0(SD 17.0),优于抗NMDAR阴性患者的53.5(SD 16.3)(d=0.52,p=0.014)。
关键数值与推荐
- 血清抗NMDAR抗体阳性率为3.7%(41/1114),各队列范围3.1-4.0%。
- 阴性症状PANSS子量表:阳性患者15.8(SD 6.4)vs 阴性患者18.2(SD 6.8),Cohen's d=0.36,p=0.026。
- 一般症状PANSS子量表:阳性患者32.9(SD 8.9)vs 阴性患者36.1(SD 10.1),d=0.33,p=0.029。
- PANSS总分:阳性患者65.5(SD 18.5)vs 阴性患者72.6(SD 19.3),d=0.37,p=0.013。
- PSP评分:阳性患者62.0(SD 17.0)vs 阴性患者53.5(SD 16.3),d=0.52,p=0.014。
临床怎么用
- 原文未据此给出推荐。
- 作者认为血清抗NMDAR抗体可能与不同形式的精神病性障碍相关,但该发现有待在其他地理区域的队列中重复。
- 作者指出这些发现可为未来预后和干预研究提供信息,以检验抗NMDAR抗体是否与特定病程或治疗反应相关。
局限性
- 所有分析均为探索性,未对多重检验进行调整。
- 研究结果有待在其他地理区域的队列中重复。
- 有生活经验者未参与本研究实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibodies against the N-methyl-D-aspartate receptor (NMDAR) have been described in the serum of people with schizophrenia spectrum disorders (schizophrenia). However, the prevalence and clinical relevance of these antibodies in schizophrenia is unclear. This knowledge gap includes the possibility of such antibodies being associated with a distinct clinical profile, which in turn might warrant a distinct treatment approach. We aimed to assess the seroprevalence of anti-NMDAR antibodies in schizophrenia, and compare symptoms and psychosocial functioning between patients with schizophrenia who were seropositive and seronegative for these antibodies. METHODS: In this case-control comparison, by combining new and existing studies, we included patients diagnosed with schizophrenia from four independent cohorts for whom anti-NMDAR serostatus had been assessed (or could be assessed by us) with live cell-based assays. Included cohorts were from the EULAST study (a trial conducted across 15 European countries and Israel), the OPTiMiSE study (an interventional study in Europe), and the PPiP1 and PPiP2 studies (conducted in the UK). Patients from these cohorts were analysed if they had complete Positive and Negative Syndrome Scale (PANSS) data. No participant had been diagnosed with autoimmune encephalitis or received treatment for this condition. After calculating the prevalence of serum anti-NMDAR antibodies, we examined possible differences in PANSS scores (negative, positive, and general symptom subscales, and total score) between anti-NMDAR-seropositive and anti-NMDAR-seronegative patients. Psychosocial functioning as measured by Personal Social Performance (PSP) score was also compared. All analyses were exploratory and no adjustment was done for multiple testing. People with lived experience were not involved in the conduct of this study. FINDINGS: We collected individual patient data from 1114 patients with schizophrenia across the four cohorts. The study population had a mean age of 28·6 years (SD 7·6) and comprised 382 (34·3%) women and 732 (65·7%) men, including patients of White (929 [83·4%]), Asian (54 [4·8%]), Black (68 [6·1%]), and other (62 [5·6%]) ethnicities. Overall, 41 (3·7%) participants (range 3·1-4·0% across cohorts) tested positive for serum anti-NMDAR antibodies. Lower symptom severity on the negative symptoms PANSS subscale was observed for anti-NMDAR-seropositive patients (mean score 15·8 [SD 6·4]) than for anti-NMDAR-seronegative patients (18·2 [6·8]; Cohen's d=0·36; p=0·026), as well as on the general symptoms PANSS subscale (32·9 [8·9] vs 36·1 [10·1]; d=0·33; p=0·029) and total PANSS score (65·5 [18·5] vs 72·6 [19·3]; d=0·37; p=0·013). Mean PSP score was better in anti-NMDAR-positive patients (62·0 [17·0]) than in anti-NMDAR-negative patients (53·5 [16·3]; d=0·52; p=0·014). INTERPRETATION: Serum NMDAR antibodies are present in 3-4% of patients with schizophrenia and are associated with relatively low severity of negative symptoms and relatively good psychosocial functioning. Thus, although the findings await replication in cohorts from other geographical regions, serum anti-NMDAR antibodies might be associated with a different form of psychotic illness. These findings could inform future prognostic and interventional studies examining whether anti-NMDAR antibodies are associated with a specific course of illness or with treatment response. FUNDING: None.
引用
- Luykx JJ, Visscher R, Winter-van Rossum I, et al. Clinical symptoms and psychosocial functioning in patients with schizophrenia spectrum disorders testing seropositive for anti-NMDAR antibodies: a case-control comparison with patients testing negative. Lancet Psychiatry. 2024. PMID: 39300641. doi:10.1016/S2215-0366(24)00249-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。